Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$1.18 USD
-0.05 (-4.07%)
Updated May 13, 2024 04:00 PM ET
After-Market: $1.18 0.00 (0.00%) 6:08 PM ET
2-Buy of 5 2
F Value B Growth F Momentum F VGM
Price, Consensus and EPS Surprise
APTO 1.18 -0.05(-4.07%)
Will APTO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for APTO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APTO
What Makes Aptose Biosciences (APTO) a New Buy Stock
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
APTO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Annovis Bio (ANVS) This Year?
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why
Horizon (HZNP) Completes Enrollment in Phase IV TED Study
Other News for APTO
Notable earnings after Tuesday's close
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
Aptose Biosciences Unveils Q1 Results and Clinical Update
Aptose Biosciences Announces Vital Update; Not SEC Filed
Aptose Biosciences Enhances Executive Compensation and Roles